Enterprise Therapeutics

The sun is shining, buds have sprouted, color is popping up everywhere — and it’s all because of YOU! 🌸💜 Thank you for joining us at the 2024 Evening with Emily’s Entourage “Efflorescence” gala this past weekend. We celebrated Emily’s Entourage turning 13 — a time of transformation where you outgrow who you were and blossom into who you are meant to become. And blossom, we did, raising a truly efflorescent.... $1.34 MILLION (!!) ...and counting! A HUGE, resounding thank you to our extraordinary sponsors, volunteers, guests, supporters, gala planning committee, staff, and leadership! We also want to extend our most heartfelt gratitude to our special honorees, The Borgioni Family, in loving memory of Michael! Thank you, mighty Entourage, for opening your hearts and believing in our collective power to put an end to this awful disease. You give us faith that together, we can create a future where we can all, 100% of us, finally breathe easier. TOGETHER, LET’S BLOOM 🌸🌺 . . . #EEfflorescence #CureCF #cysticfibrosis #CF #CFResearch

Last week we attended the annual Emily's Entourage gala in Philadelphia, an opportunity for the #CF community to come together to help raise essential funds and awareness to support the 10% of people with cystic fibrosis that aren’t able to benefit from CTFR-targeted treatments.   Learn more about how Emily's Entourage is combating #CF: https://bit.ly/3avffr3    Our CEO John Ford said “We were delighted to see this event so well-attended, a credit to the support of the CF community. the speeches were inspiring and reminded me that we must continue to do everything in our power to urgently get new treatments to the last 10%. Special thanks to Coby and Emily for doing such a great job of hosting the evening!”   📷 Photo credits: Emily’s Entourage and Enterprise Therapeutics. The EE gala; Emily and Coby Kramer-Golinkoff; Dr John Ford, CEO; Dr Renu Gupta, CMO; Phil Boyd, CFO. 

We were impressed with the content presented at the North American Cystic Fibrosis Conference last week, across tracks including ‘Airway, Physiology, Pathophysiology and Therapeutic Targeting’, and ‘The Path to Cure/CTFR Biology’. For more information on the event organised by the Cystic Fibrosis Foundation read here: https://bit.ly/4dLTd6r If you would like to speak with us following the conference, please reach out: info@enterprisetherapeutics.com #cysticfibrosis #cf

We’re sponsoring and attending the Emily's Entourage annual gala on Saturday 5th October! We are proud to support the work that Emily's Entourage is doing towards ensuring treatments are available for the final 10% of people with #cysticfibrosis who do not benefit from #CTFR-targeted therapies. This event aims to raise crucial funding and awareness, to support the organisation’s vital work. Read here to find out more about the gala: https://bit.ly/3Md60TE

We have been granted ‘rare pediatric disease designation’ (RPD) in the US by the Food and Drug Administration (FDA) for our novel investigational therapy, ETD001, designed for the treatment of Cystic Fibrosis (CF).   The RPD designation was based on the assessment of CF as a serious or life-threatening disease, primarily affecting individuals aged from birth to 18 years.   Earlier this year we commenced phase 2 clinical trials of ETD001, which aim to assess the safety and efficacy in the 10% of people with CF (pwCF) who are ineligible for or not receiving CTFR modulator therapy. Read the full press release here: https://bit.ly/4eEZt0g

Our CEO John Ford, CMO Renu Gupta, M.D, Head of Development Paul Russell, Head of Biology Henry Danahay and COO/CSO Martin Gosling will be at the North American Cystic Fibrosis Conference (NACFC) conference in Boston next week. Bringing together scientists, clinicians and caregivers from around the globe to discuss the most recent developments in #CF research, care and #drugdevelopment, the aim of this conference is to improve the health and quality of life of people with #CF. Learn more about NACFC and the Cystic Fibrosis Foundation here: https://bit.ly/4cxGbbu If you’re interested to hear more about our lead candidate ETD001, designed to treat people with #CF with the highest unmet medical need, why not arrange a meeting with us: 📧 info@enterprisetherapeutics.com

We’re delighted to have been selected as a finalist for ‘Biotech Company of the Year’ at this year’s SCRIP Awards!   The shortlisting is in recognition of our achievements over the past year, including a successful Series B fundraising, the progression of our lead candidate ETD001 to Phase 2 clinical trials, the publication of high-profile peer-review papers, and several key strategic appointments.   Congratulations to all of the finalists – we look forward to seeing everyone at the awards ceremony in London on 4th December!

We have appointed Annabella Amatulli to the newly created role of Head of Regulatory Affairs. Annabella will drive Enterprise’s regulatory strategy while working closely with clinical, medical, patient engagement and market access teams. She will play a pivotal role in supporting the ongoing Phase 2 clinical trial of our lead asset ETD001, for the treatment of #cysticfibrosis (#CF). With more than 14 years’ experience working in regulatory affairs in pharmaceutical companies, Annabella has led interactions with global health authorities, including EMA, FDA, MHRA and NMPA, to obtain approvals for numerous drug candidates. Read the full press release here: https://rb.gy/lsb3zj

🌸 Efflorescence (noun): the action or process of developing and unfolding as if coming into flower. ✨ This year, Emily’s Entourage turns 13, and we want YOU to join us in celebrating this incredible coming-of-age moment at the 2024 EE Gala: Efflorescence For so long, we've been planting seeds of hope for the final 10% of the #cysticfibrosis community, tirelessly working to advance scientific breakthroughs. Now, we’re beginning to witness the beautiful fruits of our labor — tangible, life-saving breakthroughs for those who do not benefit from current mutation-targeted therapies. 🌱 The buds have sprouted; EE is in bloom. 🌺 Inspired by the magical moments just before a flower bursts forth into its fullest glory, this year’s gala represents our journey from hopeful beginnings to the blossoming of real change and measurable progress. 🌱💜 Join us for an unforgettable evening as we experience the petals unfurl and EE blossom for the world to see. Let’s bloom together! 🌸 2024 Evening with Emily’s Entourage Gala Saturday, Oct. 5, 2024, at 7 p.m. The Mann Center for the Performing Arts, Philadelphia, PA Register and learn more >> https://lnkd.in/d-HzqFQe . . . #EEflorescence #EEAnnualGala #CysticFibrosis #nonprofit

We have commenced dosing in a phase 2a clinical trial for our lead candidate ETD001, for people with cystic fibrosis (pwCF).   Cystic fibrosis results in failed mucociliary clearance and mucus congestion in the lungs. ETD001 is a novel drug aimed at increasing the hydration and clearance of mucus by targeting the epithelial sodium channel (ENaC) in the airway epithelium.   This Phase 2a trial aims to deliver clinical proof-of-concept and to assess the safety profile of ETD001 in the >10% of pwCF without an effective current therapy. ETD001 has previously demonstrated a strong safety profile in healthy participants, in a Phase 1 trial, and has been shown to be long-acting in pre-clinical studies.   Learn more: https://lnkd.in/gYXeug-D